| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ALL ISSUES | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Article |
From the Departments of Psychiatry and the Behavioral Sciences (LSS, KD) and Neurology (LSS), Keck School of Medicine; the Leonard Davis School of Gerontology (LSS); and the Department of Preventive Medicine, Division of Biometry (PSI), University of Southern California, Los Angeles.
Objective: Atypical antipsychotic medications are widely used to treat delusions, aggression, and agitation in people with Alzheimer disease (AD) and other dementia. Several clinical trials have not shown efficacy, and there have been concerns about adverse events. The objective of this study was to assess the evidence for efficacy and adverse events of atypicals for people with dementia
Methods: MEDLINE, the Cochrane Register of Controlled Trials, meetings, presentations, and information obtained from sponsors were used in this study. Published and unpublished randomized, placebo-controlled, double-blind, parallel-group trials in patients with AD or dementia of atypical antipsychotics marketed in the United States were studied. Clinical and trials characteristics, outcomes, and adverse events were extracted. Data were checked by a second reviewer. Fifteen trials including 16 contrasts of atypical antipsychotics with placebo met selection criteria: aripiprazole (k = 3), olanzapine (k = 5), quetiapine (k = 3), and risperidone (k = 5). A total of 3,353 patients were randomized to drug and 1,757 to placebo. Standard meta-analysis methods were used to summarize outcomes.
Results: Quality of the reporting of trials varied. Efficacy on rating scales was observed by meta-analysis for aripiprazole and risperidone, but not for olanzapine. Response rates were frequently not reported. There were smaller effects for less severe dementia, outpatients, and patients selected for psychosis. Approximately one-third dropped out without overall differences between drug and placebo. Adverse events were mainly somnolence and urinary tract infection or incontinence across drugs, and extrapyramidal symptoms or abnormal gait with risperidone or olanzapine. Cognitive test scores worsened with drugs. There was no evidence for increased injury, falls, or syncope. There was a significant risk for cerebrovascular events, especially with risperidone; increased risk for death overall was reported elsewhere.
Conclusions: Small statistical effect sizes on symptom rating scales support the evidence for the efficacy of aripiprazole and risperidone. Incomplete reporting restricts estimates of response rates and clinical significance. Dropouts and adverse events further limit effectiveness. Atypicals should be considered within the context of medical need and the efficacy and safety of alternatives. Individual patient meta-analyses are needed to better assess clinical significance and effectiveness.
Key Words: Antipsychotic • meta-analysis • Alzheimer disease • dementia • clinical trials • atypicals
This article has been cited by other articles:
|
|
 |
|
  H. Lavretsky Neuropsychiatric Symptoms in Alzheimer Disease and Related Disorders: Why Do Treatments Work in Clinical Practice but Not in the Randomized Trials? Am J Geriatr Psychiatry, July 1, 2008; 16(7): 523 - 527. [Full Text] [PDF]
|
|
|
|
|
|
G. Selbaek, O. Kirkevold, and K. Engedal The Course of Psychiatric and Behavioral Symptoms and the Use of Psychotropic Medication in Patients With Dementia in Norwegian Nursing Homes--A 12-Month Follow-Up Study Am J Geriatr Psychiatry, July 1, 2008; 16(7): 528 - 536. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Streim, A. P. Porsteinsson, C. D. Breder, R. Swanink, R. Marcus, R. McQuade, and W. H. Carson A Randomized, Double-Blind, Placebo-Controlled Study of Aripiprazole for the Treatment of Psychosis in Nursing Home Patients with Alzheimer Disease Am J Geriatr Psychiatry, July 1, 2008; 16(7): 537 - 550. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Rochon, S.-L. Normand, T. Gomes, S. S. Gill, G. M. Anderson, M. Melo, K. Sykora, L. Lipscombe, C. M. Bell, and J. H. Gurwitz Antipsychotic Therapy and Short-term Serious Events in Older Adults With Dementia Arch Intern Med, May 26, 2008; 168(10): 1090 - 1096. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Smith, K. C. Buckwalter, H. Kang, V. Ellingrod, and S. K. Schultz Dementia-Specific Assisted Living: Clinical Factors and Psychotropic Medication Use Journal of the American Psychiatric Nurses Association, March 1, 2008; 14(1): 39 - 49. [Abstract] [PDF]
|
|
|
|
 |
|
 J. O. Brooks and J. C. Hoblyn Neurocognitive Costs and Benefits of Psychotropic Medications in Older Adults J Geriatr Psychiatry Neurol, December 1, 2007; 20(4): 199 - 214. [Abstract] [PDF]
|
|
|
|
 |
|
 How safe are antipsychotics in dementia? DTB, November 1, 2007; 45(11): 81 - 85. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Ballard Agitation and Psychosis in Dementia Am J Geriatr Psychiatry, November 1, 2007; 15(11): 913 - 917. [Full Text] [PDF]
|
|
|
|
|
|
B. G. Pollock, B. H. Mulsant, J. Rosen, S. Mazumdar, R. E. Blakesley, P. R. Houck, and K. A. Huber A Double-Blind Comparison of Citalopram and Risperidone for the Treatment of Behavioral and Psychotic Symptoms Associated With Dementia Am J Geriatr Psychiatry, November 1, 2007; 15(11): 942 - 952. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Rosenheck, D. L. Leslie, J. L. Sindelar, E. A. Miller, P. N. Tariot, K. S. Dagerman, S. M. Davis, B. D. Lebowitz, P. Rabins, J. K. Hsiao, et al. Cost-Benefit Analysis of Second-Generation Antipsychotics and Placebo in a Randomized Trial of the Treatment of Psychosis and Aggression in Alzheimer Disease Arch Gen Psychiatry, November 1, 2007; 64(11): 1259 - 1268. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Howard, E. Juszczak, C. G. Ballard, P. Bentham, R. G. Brown, R. Bullock, A. S. Burns, C. Holmes, R. Jacoby, T. Johnson, et al. Donepezil for the Treatment of Agitation in Alzheimer's Disease N. Engl. J. Med., October 4, 2007; 357(14): 1382 - 1392. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. C. Kales, M. Valenstein, H. M. Kim, J. F. McCarthy, D. Ganoczy, F. Cunningham, and F. C. Blow Mortality Risk in Patients With Dementia Treated With Antipsychotics Versus Other Psychiatric Medications Am J Psychiatry, October 1, 2007; 164(10): 1568 - 1576. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Lyketsos Apathy and Agitation: Challenges and Future Directions Am J Geriatr Psychiatry, May 1, 2007; 15(5): 361 - 364. [Full Text] [PDF]
|
|
|
|
|
|
H. M. Hussain, M. Hotopf, F. Oyebode, M. C. Jockers-Scherubl, R. Hellweg, L. S. Schneider, P. N. Tariot, and D. Weintraub Atypical Antipsychotic Drugs and Alzheimer's Disease N. Engl. J. Med., January 25, 2007; 356(4): 416 - 418. [Full Text] [PDF]
|
|
|
|
 |
|
 M. T. Beier Pharmacotherapy for behavioral and psychological symptoms of dementia in the elderly Am. J. Health Syst. Pharm., January 15, 2007; 64(2_Supplement_1): S9 - S17. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Golden and B. Lawlor Treatment of dementia in the community BMJ, December 9, 2006; 333(7580): 1184 - 1185. [Full Text] [PDF]
|
|
|
|
 |
|
 G. J Byrne Training nursing home staff to improve psychosocial care reduces neuroleptic use in people with dementia without an increase in agitation. Evid. Based Ment. Health, November 1, 2006; 9(4): 103 - 103. [Full Text] [PDF]
|
|
|
|
|
|
L. S. Schneider, P. N. Tariot, K. S. Dagerman, S. M. Davis, J. K. Hsiao, M. S. Ismail, B. D. Lebowitz, C. G. Lyketsos, J. M. Ryan, T. S. Stroup, et al. Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's Disease. N. Engl. J. Med., October 12, 2006; 355(15): 1525 - 1538. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Karlawish Alzheimer's disease -- clinical trials and the logic of clinical purpose. N. Engl. J. Med., October 12, 2006; 355(15): 1604 - 1606. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Smith, T. Rahman, N. Toohey, J. Mazurkiewicz, K. Herrick-Davis, and M. Teitler Risperidone Irreversibly Binds to and Inactivates the h5-HT7 Serotonin Receptor Mol. Pharmacol., October 1, 2006; 70(4): 1264 - 1270. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. N. Tariot Neuropsychiatric Features of Dementia: What is the Big Picture? Am J Geriatr Psychiatry, July 1, 2006; 14(7): 557 - 560. [Full Text] [PDF]
|
|
|
|
 |
|
 H. Lavretsky and L. H. Nguyen Innovations: Geriatric Psychiatry: Diagnosis and Treatment of Neuropsychiatric Symptoms in Alzheimer's Disease Psychiatr Serv, May 1, 2006; 57(5): 617 - 619. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ALL ISSUES | SEARCH | TABLE OF CONTENTS |
